A phase II study of the histone deacetylase inhibitor panobinostat (LBH589) in pretreated patients with small-cell lung cancer

Journal of Thoracic Oncology

Volumn 8, Issue 8, 2013, Pages 1091-1094

  De Marinis, Filippo ^a   Atmaca, Akin ^b   Tiseo, Marcello ^c   Giuffreda, Libero ^d   Rossi, Antonio ^e   Gebbia, Vittorio ^f   D'Antonio, Chiara ^a   Zotto, Laura Dal ^g   Al Batran, Salah Eddin ^b   Marsoni, Silvia ^g   Wolf, Martin ^h  

^a SAN CAMILLO FORLANINI HOSPITAL   (Italy)

^b KRANKENHAUS NORDWEST   (Germany)

^c UNIVERSITY HOSPITAL OF PARMA   (Italy)

^d MOLINETTE HOSPITAL   (Italy)

^e S G MOSCATI HOSPITAL   (Italy)

^f UNIVERSITY OF PALERMO   (Italy)

^g Southern Europe New Drug Organization Foundation   (Italy)

^h KLINIKUM KASSEL   (Germany)

Author keywords

Deacetylase inhibitor; LBH58; Panobinostat; Phase II trial; Small cell lung cancer

Indexed keywords

PANOBINOSTAT;

ADULT; AGED; ANEMIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; ASTHENIA; CLINICAL ARTICLE; CONSTIPATION; DIARRHEA; DISEASE COURSE; DRUG EFFICACY; DRUG TOLERABILITY; FATIGUE; FEMALE; HUMAN; LUNG SMALL CELL CANCER; MALE; MEDICATION COMPLIANCE; MULTICENTER STUDY; NAUSEA; PATIENT COMPLIANCE; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; THROMBOCYTOPENIA; TREATMENT RESPONSE; VOMITING;

AGED; ANTINEOPLASTIC AGENTS; FEMALE; HISTONE DEACETYLASE INHIBITORS; HUMANS; HYDROXAMIC ACIDS; INDOLES; LUNG NEOPLASMS; MALE; MIDDLE AGED; SMALL CELL LUNG CARCINOMA;

EID: 84880886469     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0b013e318293d88c     Document Type: Article

References (18)

1. Sandler AB. Chemotherapy for small cell lung cancer. Semin Oncol 2003;30:9-25.
2. Murray N, Turrisi III AT. A review of first-line treatment for small cell lung cancer. J Thorac Oncol 2006;1:270-8.
3. Sundstrøm S, Bremnes RM, Kaasa S, et al.; Norwegian Lung Cancer Study Group. Cisplatin and etoposide regimen is superior to cyclophosphamide, epirubicin, and vincristine regimen in small-cell lung cancer: results from a randomized phase III trial with 5 years' follow-up. J Clin Oncol 2002;20:4665-4672.
4. Riemsma R, Simons JP, Bashir Z, Gooch CL, Kleijnen J. Systematic Review of topotecan (Hycamtin) in relapsed small cell lung cancer. BMC Cancer 2010;10:436.
5. von Pawel J, Schiller JH, Shepherd FA, et al. Topotecan versus cyclophosphamide, doxorubicin, and vincristine for the treatment of recurrent small-cell lung cancer. J Clin Oncol 1999;17:658-667.
6. Minucci S, Pelicci PG. Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer. Nat Rev Cancer 2006;6:38-51.
7. Bolden JE, Peart MJ, Johnstone RW. Anticancer activities of histone deacetylase inhibitors. Nat Rev Drug Discov 2006;5:769-784.
8. Mehnert JM, Kelly WK. Histone deacetylase inhibitors: biology and mechanism of action. Cancer J 2007;13:23-29.
9. Garber K. HDAC inhibitors overcome first hurdle. Nat Biotechnol 2007;25:17-19.
10. Crisanti MC, Wallace AF, Kapoor V, et al. The HDAC inhibitor panobinostat (LBH589) inhibits mesothelioma and lung cancer cells in vitro and in vivo with particular efficacy for small cell lung cancer. Mol Cancer Ther 2009;8:2221-2231.
11. Edwards A, Li J, Atadja P, Bhalla K, Haura EB. Effect of the histone deacetylase inhibitor LBH589 against epidermal growth factor receptor- dependent human lung cancer cells. Mol Cancer Ther 2007;6: 2515-2524.
12. Luszczek W, Cheriyath V, Mekhail TM, Borden EC. Combinations of DNA methyltransferase and histone deacetylase inhibitors induce DNA damage in small cell lung cancer cells: correlation of resistance with IFN-stimulated gene expression. Mol Cancer Ther 2010;9:2309-2321.
13. Crisanti MC, Wallace AF, Kapoor V, et al. The HDAC inhibitor panobinostat (LBH589) inhibits mesothelioma and lung cancer cells in vitro and in vivo with particular efficacy for small cell lung cancer. Mol Cancer Ther 2009;8:2221-2231.
14. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000;92:205-216.
15. Cancer Therapy Evaluation Program, Common Terminology Criteria for Adverse Events, Version 3.0. Available at: http://ctep.cancer.gov. Accessed August 9, 2006.
16. Simon R, Wittes RE, Ellenberg SS. Randomized phase II clinical trials. Cancer Treat Rep 1985;69:1375-1381.
17. Ramalingam SS. Histone deacetylase inhibitors. J Thorac Oncol 2011;6(11 Suppl 4):S1808-S1809.
18. Cesano A, Lane SR, Poulin R, et al. Stabilization of disease as a useful predictor of survival following second- line chemotherapy in small cell lung cancer and ovarian cancer patients. Int J Oncol 1999;15:1233-8.